US64049M2098
© BusinessWire
10.12.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present New ctDNA Research at SABCS 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that data utilizing its RaDaR® 1.0 assay for the detection of molecular residual disease (MRD) will be presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place Dec. 9–12, 2025, at the Henry B....
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present Real-World Study on Comprehensive Genomic Profiling in Myeloid Malignancies at ASH 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new data demonstrating how comprehensive genomic profiling (CGP) can refine diagnosis and guide treatment decisions for patients with myeloid malignancies at the 67th American Society of Hematology (ASH) Annual Meeting,...
Themefolio
Profiler
Peergroup
© BusinessWire
06.11.2025
NEO
LISTED
NASDAQ
NeoGenomics to Participate in Upcoming Investor Conferences
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the Company will participate in the following investor conferences:
Stephens Annual Investment Conference in Nashville, TN
Company presentation on Wednesday, November 19, at 1:00 pm CT, accessible here
Piper Sandl...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
30.10.2025
NEO
LISTED
NASDAQ
NeoGenomics to Present RaDaR ST Bridging Study at ISLB 2025, Demonstrating Reliable MRD Detection Across Solid Tumors
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will present new research at the International Society of Liquid Biopsy (ISLB) Annual Congress 2025 demonstrating high concordance between its RaDaR® ST and RaDaR® 1.0 assays for detecting molecular residual disease (MRD) in solid t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
28.10.2025
NEO
LISTED
NASDAQ
NeoGenomics Reports Third Quarter 2025 Results
News Preview
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its third quarter results for the period ended September 30, 2025.
Third Quarter 2025 Highlights As Compared To Third Quarter 2024
Consolidated revenue increased 12% to a record...
Themefolio
Profiler
Peergroup
© BusinessWire
14.10.2025
NEO
LISTED
NASDAQ
NeoGenomics to Highlight RaDaR ST MRD Assay at ESMO Congress 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the presentation of assay-relevant data, including interventional therapy trials in progress, to showcase how its molecular residual disease (MRD) assay may benefit pharmaceutical partners at the European Society for...
Themefolio
Profiler
Peergroup
© BusinessWire
07.10.2025
NEO
LISTED
NASDAQ
NeoGenomics to Report Third Quarter 2025 Financial Results on October 28, 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its third quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, October 28, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2025
NEO
LISTED
NASDAQ
Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera
News Preview
NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the District Court for the Middle District of North Carolina has granted NeoGenomics’ motion for summary judgment that all of Natera’s asserted patent claims are invalid for claiming ineligible subject matter. The Cou...
Themefolio
Profiler
Peergroup
© BusinessWire
30.07.2025
NEO
LISTED
NASDAQ
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company’s PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, tria...
Themefolio
Profiler
Peergroup
© BusinessWire
29.07.2025
NEO
LISTED
NASDAQ
NeoGenomics Reports Second Quarter 2025 Results
News Preview
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its second-quarter results for the period ended June 30, 2025.
Second Quarter 2025 Highlights As Compared To Second Quarter 2024
Consolidated revenue increased 10% to record $18...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
NEO
LISTED
NASDAQ
NeoGenomics to Report Second Quarter 2025 Financial Results on July 29, 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its second quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, July 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to d...
Themefolio
Profiler
Peergroup
© BusinessWire
30.06.2025
NEO
LISTED
NASDAQ
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insi...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.06.2025
NEO
LISTED
NASDAQ
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck.
Dr. Green, a seasoned e...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
NEO
LISTED
NASDAQ
NeoGenomics Debuts PanTracer Family of Genomic Profiling Tests at ASCO 2025
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, will debut its PanTracer™ Family, a comprehensive suite of genomic profiling tests for advanced solid tumors, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30...
Themefolio
Profiler
Peergroup
© BusinessWire
22.05.2025
NEO
LISTED
NASDAQ
NeoGenomics Launches c-MET CDx Assay to Guide Treatment Decisions for Advanced Non-Small Cell Lung Cancer
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, today announced the commercial launch of c-MET CDx for NSCLC, its c-MET companion diagnostic immunohistochemistry (IHC) assay. The test is now available to oncologists and pathologists nationwide, supporting treatment selection for patients with advanced non-small ce...
Themefolio
Profiler
Peergroup
© BusinessWire
20.05.2025
NEO
LISTED
NASDAQ
NeoGenomics to Participate in Upcoming June Investor Conferences
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:
William Blair 45th Annual Growth Stock Conference in Chicago, IL
Company presentation on Tuesday, June 3, at 1:00 pm ET, accessible here
Jefferies Glob...
Themefolio
Profiler
Peergroup
© BusinessWire
01.05.2025
NEO
LISTED
NASDAQ
NeoGenomics Pays Off 1.25% Convertible Senior Notes
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading provider of oncology testing services, today announced that it has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes with a maturity date of May 1, 2025, using cash on hand.
About NeoGenomics, Inc.
NeoGen...
Themefolio
Profiler
Peergroup
© BusinessWire
29.04.2025
NEO
LISTED
NASDAQ
NeoGenomics Reports First Quarter 2025 Results
News Preview
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced its first-quarter results for the period ended March 31, 2025.
First Quarter 2025 Highlights As Compared To First Quarter 2024
Consolidated revenue increased 8% to $168 million
Net los...
Themefolio
Profiler
Peergroup
© BusinessWire
22.04.2025
NEO
LISTED
NASDAQ
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the analytical validation of its PanTracer LBx™ assay, a next-generation sequencing (NGS) liquid biopsy panel designed for comprehensive pan-solid tumor profiling. The validation study, along with five additional abstra...
Themefolio
Profiler
Peergroup
© BusinessWire
08.04.2025
NEO
LISTED
NASDAQ
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to d...
Themefolio
Profiler
Peergroup
© BusinessWire
07.04.2025
NEO
LISTED
NASDAQ
NeoGenomics Completes Acquisition of Pathline
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced it has completed its previously announced acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey.
With the acquisition, NeoGenomics strengthens its comm...
Themefolio
Profiler
Peergroup
© BusinessWire
01.04.2025
NEO
LISTED
NASDAQ
Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along...
Themefolio
Profiler
Peergroup
© BusinessWire
18.03.2025
NEO
LISTED
NASDAQ
NeoGenomics Appoints Warren Stone as President & Chief Operating Officer
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced that it has promoted Warren Stone, the Company’s current Chief Commercial Officer (CCO), to President & Chief Operating Officer, effective April 1, 2025.
Mr. Stone has over 25 yea...
Themefolio
Profiler
Peergroup
© BusinessWire
10.03.2025
NEO
LISTED
NASDAQ
NeoGenomics Expands Oncology Testing Reach in the Northeast with Acquisition of Pathline
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology testing services, today announced the acquisition of Pathline, LLC, a CLIA/CAP/NYS-certified laboratory based in New Jersey. The acquisition strengthens NeoGenomics’ commercial presence in the Northeast U.S., expanding its service capabilities and accel...
Themefolio
Profiler
Peergroup
© BusinessWire
24.02.2025
NEO
LISTED
NASDAQ
NeoGenomics to Participate in Upcoming Investor Conferences
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced the Company will participate in the following investor conferences:
TD Cowen 45th Annual Health Care Conference in Boston, MA
Fireside chat on Tuesday, March 4 at 1:50 p.m. ET, accessible here
Leerink Partners Global He...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
NEO
LISTED
NASDAQ
NeoGenomics Reports Fourth Quarter and Full Year 2024 Results
News Preview
NeoGenomics, Inc. (Nasdaq: NEO) (the “Company”), a leading oncology testing services company, today announced its fourth-quarter and full year results for the period ended December 31, 2024.
Fourth Quarter and Full Year 2024 Highlights
Fourth quarter consolidated revenue increased 11% to $172 million; Full year consolidated revenue increa...
Themefolio
Profiler
Peergroup
© BusinessWire
29.01.2025
NEO
LISTED
NASDAQ
NeoGenomics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18, 2025
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2024 financial results prior to the open of the U.S. financial markets on Tuesday, February 18, 2025. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial resu...
Themefolio
Profiler
Peergroup
© BusinessWire
15.01.2025
NEO
LISTED
NASDAQ
NeoGenomics Provides 2025 Financial Guidance and Updates Long-Range Financial Plan
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today provided financial guidance for fiscal year 2025 and updated its Long-Range Financial Plan.
“We enter 2025 with our patient-centric strategy in place, focusing on product innovation, further optimization and expansion of our commer...
Themefolio
Profiler
Peergroup
© BusinessWire
10.01.2025
NEO
LISTED
NASDAQ
NeoGenomics Announces Chief Executive Officer Succession
News Preview
NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading oncology testing services company, today announced that Chris Smith will retire as Chief Executive Officer (CEO) and board member effective April 1, 2025. Tony Zook, an independent board member since 2023, will assume the role of CEO at that time.
“Chris has provided exce...
Themefolio
Profiler
Peergroup
© BusinessWire
06.01.2025
NEO
LISTED
NASDAQ
NeoGenomics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California. Chris Smith, Chief Executive Officer, will deliver a presentation followed by Q&A on Wednesday, January 15, at 1:30 p.m. PT/4:30 p.m. ET.
The presentation will be webcast li...
Themefolio
Profiler
Peergroup
© BusinessWire
11.12.2024
NEO
LISTED
NASDAQ
NeoGenomics’ Newly Published Study Underscores Potential of ctDNA as a Predictive Tool for Monitoring Patients with High-Risk Melanoma
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced the recent publication of a new study in ESMO Open, demonstrating how circulating tumor DNA (ctDNA) in monitoring molecular residual disease (MRD) may enable earlier identification of disease recurrence for high-risk melanoma patients.
Melanoma impacted over...
Themefolio
Profiler
Peergroup
© BusinessWire
09.12.2024
NEO
LISTED
NASDAQ
NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system (CNS) lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting, booth #2347, in San Diego, December 7-10...
Themefolio
Profiler
Peergroup
© BusinessWire
19.11.2024
NEO
LISTED
NASDAQ
NeoGenomics to Present New Data at AMP 2024, Highlighting the Impact of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present four abstracts at the Association for Molecular Pathology (AMP) 2024 Annual Meeting & Expo in Vancouver, Canada, November 19-23 (booth #830). The research demonstrates how ctDNA and next-generation sequencing (NGS) can drive more personalized and accurat...
Themefolio
Profiler
Peergroup
© BusinessWire
14.11.2024
NEO
LISTED
NASDAQ
Felicia Williams Joins NeoGenomics Board of Directors
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced the appointment of Felicia Williams to its Board of Directors.
“We are fortunate to welcome Felicia Williams to our board of directors, bringing her experience across the spectrum of finance, accounting, audit, and enterprise risk management to NeoGenom...
Themefolio
Profiler
Peergroup
© BusinessWire
08.11.2024
NEO
LISTED
NASDAQ
NeoGenomics to Participate in the Piper Sandler 36th Annual Healthcare Conference
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Piper Sandler 36th Annual Healthcare Conference. Members of the management team will participate in an in-person fireside chat on Thursday, Dec. 5, 2024, at 9:30 a.m. ET in New York City.
The presentation will be webcast live and accessible online via th...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2024
NEO
LISTED
NASDAQ
NeoGenomics Reports Third Quarter 2024 Results
News Preview
NeoGenomics, Inc. (NASDAQ: NEO) (the “Company”), a leading oncology testing services company, today announced its third-quarter results for the period ended September 30, 2024.
Third Quarter 2024 Highlights As Compared To Third Quarter 2023
Consolidated revenue increased 10% to $168 million
Clinical Services revenue increased 14% to...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2024
NEO
LISTED
NASDAQ
NeoGenomics Receives New York State Approval for Neo Comprehensive™ Solid Tumor Test
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that the New York State Department of Health (NYSDOH) has granted the company conditional approval for its Neo Comprehensive Solid Tumor assay and NeoTYPE® DNA & RNA Lung, allowing for immediate commercial access in the state of New York. These next-g...
Themefolio
Profiler
Peergroup
© BusinessWire
15.10.2024
NEO
LISTED
NASDAQ
NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its third quarter 2024 financial results prior to the open of the U.S. financial markets on Tuesday, Nov. 5, 2024. Company management will host a webcast and conference call at 8:30 a.m. ET to discuss financial results and recent highl...
Themefolio
Profiler
Peergroup
© BusinessWire
08.10.2024
NEO
LISTED
NASDAQ
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, announced today the launch of AML Express, a next-generation sequencing (NGS) assay designed to provide rapid, comprehensive genetic profiling for patients with acute myeloid leukemia (AML).
“AML Express enhances our hematologic portfolio by addressing the clinical need...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2024
NEO
LISTED
NASDAQ
NeoGenomics Announces New RaDaR Technology and Resolution of RaDaR 1.0 Litigation
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today issued the following statement in response to inquiries:
NeoGenomics has cleared the feasibility stage with a new version of its RaDaR® technology and has resolved litigation with Natera regarding RaDaR 1.0. The Company will host a business update conference call...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2024
NEO
LISTED
NASDAQ
NeoGenomics to Present New Data at ESMO 2024, Highlighting the Value of ctDNA and NGS for Advancing Cancer Diagnostics and Personalized Treatment
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will present three studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain, September 13-17 (booth #438). NeoGenomics' data offers key insights into circulating tumor DNA (ctDNA) analysis and next-generation sequencing (NGS), focusin...
Themefolio
Profiler
Peergroup
© BusinessWire
29.08.2024
NEO
LISTED
NASDAQ
NeoGenomics to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
News Preview
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, will attend the Morgan Stanley 22nd Annual Global Healthcare Conference. Chris Smith, Chief Executive Officer, Jeff Sherman, Chief Financial Officer, and Warren Stone, Chief Commercial Officer, will participate in an in-person fireside chat on Friday, Sept. 6, 2024, at 1...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
